
Sign up to save your podcasts
Or


Global markets were on edge yesterday as President Trump’s newly announced 15% global tariff triggered a sharp European response and fresh trade uncertainty. Equity markets across both Europe and the US struggled, with tech stocks hit particularly hard amid renewed concerns about AI disruption in the software sector. Defensive names, meanwhile, benefited from the flight to safety, alongside a strong move in gold. Asian markets painted a mixed picture. On today’s show, we are joined by Next Generation research analyst Damien Ng who shares an update on the implications of the emerging Alzheimer’s blood test and what it means for the genomics space.
By Julius Baer5
44 ratings
Global markets were on edge yesterday as President Trump’s newly announced 15% global tariff triggered a sharp European response and fresh trade uncertainty. Equity markets across both Europe and the US struggled, with tech stocks hit particularly hard amid renewed concerns about AI disruption in the software sector. Defensive names, meanwhile, benefited from the flight to safety, alongside a strong move in gold. Asian markets painted a mixed picture. On today’s show, we are joined by Next Generation research analyst Damien Ng who shares an update on the implications of the emerging Alzheimer’s blood test and what it means for the genomics space.

977 Listeners

406 Listeners

199 Listeners

1,044 Listeners

684 Listeners

232 Listeners

191 Listeners

1,320 Listeners

80 Listeners

4 Listeners

187 Listeners

80 Listeners

194 Listeners

11 Listeners

24 Listeners